Skip to main content
. Author manuscript; available in PMC: 2010 Nov 10.
Published in final edited form as: J Comp Neurol. 2009 Nov 10;517(2):123–133. doi: 10.1002/cne.22107

Figure 2.

Figure 2

BrdU antibodies, analogs, and pretreatments produce variable histology. (A, B) BrdU-labeled cells (arrows) in the dentate gyrus from sections stained with Vector (A) or BD (B) antibodies 3 weeks after BrdU administration. High magnification examples of BrdU-labeled cells in the granule cell layer (gcl) 2h (C, D) and 3 weeks (F, G) after BrdU administration as detected with Vector (C, F) or BD (D, G). At both the 2h and 3 week timepoints, more BrdU-labeled cells were detected with the BD antibody. (E, H) High magnification examples of IdU- and CldU-labeled cells in the gcl 2h after equimolar delivery of the analogs as detected with the BD antibody. IdU and CldU labeled fewer cells than BrdU and could not be discriminated because of antibody cross-reactivity. (I-K) Immunofluorescence double-labeling of BrdU (I) and Ki67 (J). Merged image shown in (K). All BrdU-labeled cells detected with the BD antibody stained for Ki67 indicating specificity for dividing cells. (L–P) Confocal images of NeuN staining from sections pretreated with HCl alone (L), HCl + formamide (M, N) or Steam heating (O, P). HCl + formamide and Steam heating pretreatments were variable in their staining patterns, some had high background (M, O) whereas others had no nuclear staining (N, P). Scale bars, 10 µm.